Study guide

3.2 OBRA '90, Medicaid DUR & Federal Counseling Floor

Illinois MPJE Pharmacy Jurisprudence

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the Illinois MPJE 1.2 NABP Competency Areas & Weights 1.3 How to Use This Guide & Study Strategy

2 Chapter 2: Federal Controlled Substances Foundations

2.1 CSA Schedules I–V & Illinois Alignment 2.2 DEA Registration, Forms 222/106/41 & Security 2.3 Federal CS Prescription Rules (CII–CV) 2.4 Inventories, Recordkeeping & Theft/Loss

3 Chapter 3: Federal Drug Regulation, Privacy & Supply Chain

3.1 FD&C Act, Legend vs OTC, Misbranding & Adulteration 3.2 OBRA '90, Medicaid DUR & Federal Counseling Floor 3.3 HIPAA Privacy for Pharmacy 3.4 DSCSA & Drug Supply Chain Integrity

4 Chapter 4: IDFPR, Licensure & Eligibility

4.1 IDFPR Authority & Sources of Illinois Pharmacy Law 4.2 Pharmacist Licensure by Exam & Score Transfer 4.3 License Transfer (Reciprocity) & Background Checks 4.4 Interns, Preceptors & Experiential Requirements

5 Chapter 5: Renewal, CE, PIC & Discipline

5.1 License Renewal & 30-Hour Biennial CE 5.2 Pharmacist-in-Charge Duties 5.3 Discipline & Unprofessional Conduct 5.4 Impaired Practitioners & Mandatory Reporting

6 Chapter 6: Technicians, Interns & Supervision

6.1 Technician Registration, Training & Certification 6.2 Supervision, Scope & No Fixed Tech Ratio 6.3 Intern Scope, Delegation & Final Verification

7 Chapter 7: Prescription Authority & Validity

7.1 Who May Prescribe in Illinois 7.2 Prescription Content & Validity Requirements 7.3 Controlled Substance Prescribing (720 ILCS 570 + Federal) 7.4 Refills, Partial Fills & E-Prescribing Mandate

8 Chapter 8: Advanced IL Pharmacist Practice

8.1 Collaborative Practice Agreements & Clinical Services 8.2 Immunizations & Vaccine Administration 8.3 Naloxone Access & Opioid Antagonists 8.4 Drug Administration & Therapy Management

9 Chapter 9: Counseling, DUR & Patient Safety

9.1 Patient Counseling Requirements 9.2 Prospective Drug Utilization Review 9.3 Returning & Reusing Drugs

10 Chapter 10: ILPMP & Opioid Public-Health Laws

10.1 Illinois PMP Overview, Reporting & Access 10.2 Mandatory Queries, Designees & Documentation 10.3 Legitimate Medical Purpose & Red Flags

11 Chapter 11: Dispensing: Transfers, Labels & Substitution

11.1 Prescription Transfers Between Pharmacies 11.2 Labeling & Packaging of Dispensed Drugs 11.3 Generic Substitution & Product Selection 11.4 Emergency Dispensing, OTC/BTC & Pseudoephedrine

12 Chapter 12: Pharmacy Operations & Facilities

12.1 Pharmacy Permits, Classifications & Inspections 12.2 Security, Automated Systems & Self-Service Kiosks 12.3 Operational Recordkeeping & Inventories 12.4 Central Fill, Delivery & Remote Services

13 Chapter 13: Compounding & Hazardous Drugs

13.1 Sterile, Nonsterile & Hazardous Compounding 13.2 Illinois Compounding Rules & Beyond-Use Dates

14 Chapter 14: Test-Day Strategy & Final Review

14.1 When Illinois Law Is Stricter Than Federal Law 14.2 Test-Day Strategy & Common Traps

3.2 OBRA '90, Medicaid DUR & Federal Counseling Floor

Key Takeaways Explain This Topic AI

OBRA '90 created a federal Medicaid floor requiring prospective drug utilization review and an offer to counsel Medicaid outpatients, plus patient-profile and retrospective DUR infrastructure.

Prospective DUR screens therapy before dispensing for problems such as therapeutic duplication, drug-disease and drug-drug interactions, incorrect dose/duration, allergies, and clinical abuse/misuse.

Federal OBRA requires an active offer to counsel for covered Medicaid outpatient prescriptions; passive wall signs alone do not satisfy the counseling-offer concept tested on the MPJE.

States may—and Illinois does—layer counseling and DUR duties beyond the Medicaid-only federal floor; Illinois-specific counseling standards are taught in detail in Chapter 9.

On IL MPJE items, never stop at the federal floor if Illinois imposes a higher counseling or DUR duty—prevailing Illinois law controls the correct answer.

Last updated: August 2026

3.2 OBRA '90, Medicaid DUR & Federal Counseling Floor

Illinois MPJE focus: OBRA '90 is the federal floor for Medicaid prospective DUR and counseling offers. Illinois practice standards under the Pharmacy Practice Act and IDFPR rules are often stricter or broader than Medicaid-only federal text. This section builds the federal baseline; Chapter 9 teaches Illinois counseling requirements in full. If a question pits a bare "Medicaid-only offer" against Illinois counseling duties, choose Illinois.

What OBRA '90 Changed

The Omnibus Budget Reconciliation Act of 1990 (OBRA '90) transformed community pharmacy from a pure product-hand-off model into a patient-safety model. Congress tied Medicaid funding to state pharmacy program requirements. The statute's pharmacy core (Social Security Act provisions implementing Medicaid DUR) established three interlocking pillars:

  • Prospective drug utilization review (ProDUR) before dispensing
  • Offer to counsel Medicaid outpatients about their therapy
  • Patient profiles and retrospective DUR systems run with state oversight

Although the federal statute's counseling mandate is written around Medicaid outpatient beneficiaries, almost every state board—including Illinois through the Pharmacy Practice Act and administrative rules—incorporated and often expanded these duties so they apply in ordinary retail practice. The IL MPJE therefore tests both (a) the federal OBRA structure and (b) Illinois's layered counseling and DUR expectations.

Prospective DUR: Before the Patient Leaves

Prospective DUR is real-time review of a prescription before it is dispensed, using the patient profile and clinical screening tools. Software alerts help, but legal responsibility remains with the pharmacist . Alert fatigue is not a defense when a serious interaction or allergy is obvious from the profile.

Screening categories you must know

Federal Medicaid DUR regulations require screening that addresses problems such as:

  • Category What you look for Classic example
  • Therapeutic duplication Same drug or same class without justification Two systemic NSAIDs together
  • Drug-disease contraindications Therapy worsens a documented condition NSAID in advanced CKD
  • Drug-drug interactions Clinically significant combinations Warfarin + high-dose TMP-SMX without plan

Incorrect dosage or duration Dose too high/low or course too long/short Ketorolac beyond labeled duration limits

Drug-allergy interactions Prior hypersensitivity Amoxicillin after documented penicillin anaphylaxis

Clinical abuse or misuse Overuse, early refills, doctor shopping patterns Multiple early CII fills with red flags

Over/under-utilization Gaps or excess use relative to directions Chronic inhaler refill every 3 days

When a significant problem is identified, the pharmacist must resolve it using professional judgment: contact the prescriber, clarify with the patient, adjust therapy when authorized, refuse to dispense if necessary, and document the intervention. Ignoring a hard stop for speed or profit is exam-wrong and practice-wrong.

  • Prospective vs retrospective DUR
  • Prospective: individual patient, before this fill leaves the pharmacy

Retrospective: aggregate claims and patterns after dispensing, used by state DUR programs for education and outlier management

MPJE scenarios almost always test prospective pharmacist duties at the bench. Retrospective DUR is a program-level concept; do not confuse it with "looking back" casually after a patient already took the wrong drug at home.

Federal Counseling Floor: The "Offer"

Under OBRA '90's Medicaid framework, the pharmacy must make an offer to counsel the outpatient (or caregiver) regarding the medication. Key federal-concept points:

The offer must be meaningful and active for in-person encounters—not merely a wall sign that says "Ask if you have questions."

The patient may refuse ; counseling is not forced after a clear refusal, but the offer itself is required when the statute/rule applies.

Only a pharmacist (or, where state law allows, a supervised intern ) may provide the clinical counseling content; technicians may facilitate logistics but must not give clinical advice.

For mail-order / delivery , an offer is typically made in writing with a toll-free number for pharmacist access.

Counseling content under OBRA-style standards commonly includes drug name and description, dosage form and route, directions and duration, special directions/precautions, common severe side effects and what to do, techniques for self-monitoring, storage, refill information, and action for a missed dose—tailored to the patient and therapy.

States May Require More: Illinois Overlay (High Level)

This is the highest-yield state-floor comparison in this chapter. Memorize the federal structure here; master Illinois counseling mechanics in Chapter 9.

Topic Federal OBRA floor (exam framing) Illinois application (preview)

Who is covered Written as a Medicaid outpatient requirement Illinois practice standards apply counseling and patient-care duties beyond Medicaid-only community fills

What is required Offer to counsel Illinois often expects pharmacist-driven counseling on new therapy and professional judgment on refills—not a passive Medicaid-era wall sign alone

Who may counsel Pharmacist (or intern where allowed) for clinical content Same principle under Illinois scope rules: technicians do not provide clinical counseling

DUR Prospective review before dispensing Prospective DUR remains a pharmacist duty under federal floor and Illinois practice expectations

How to answer IL MPJE counseling items at this stage of the guide

If the stem is pure federal history ("What did OBRA '90 require of Medicaid programs?"), answer with ProDUR + counseling offer + profiles/retrospective DUR .

If the stem is an Illinois community pharmacy new Rx handoff, do not rely on "Medicaid-only" or a passive sign—expect Illinois-layered pharmacist counseling duties (details in Chapter 9).

If the stem involves a refill , look for language about judgment, therapy changes, or patient questions—counseling is not limited to brand-new therapy when clinical risk appears.

If the stem is mail-order , remember written offers and phone access still matter; remote models still require real pharmacist availability for counseling.

Patient Profiles

OBRA-era practice requires maintaining patient profiles with enough information to perform DUR: demographics, history of drugs and devices, known allergies/reactions, and pharmacist comments. Incomplete profiles produce incomplete DUR. Illinois recordkeeping and privacy rules (including HIPAA, next section) govern how those profiles are stored and shared.

Profile quality also feeds ILPMP and controlled-substance corresponding-responsibility thinking later in the guide: a profile that shows dangerous duplication is a stop-sign before bagging, whether or not the drug is controlled.

Connecting DUR to Dispensing Red Flags

Prospective DUR is the operational home for legitimate medical purpose and corresponding-responsibility thinking even when the drug is not controlled. A profile that shows dangerous duplication or allergy is a stop-sign before labeling and bagging. Documentation of interventions protects the patient and creates the record IDFPR inspectors and civil litigants look for.

When federal OBRA DUR duties, Illinois practice standards, and controlled-substance red-flag analysis all point the same way, the exam answer is almost always: resolve the problem, document, and do not dispense through a known risk for convenience .

Section Checkpoint

OBRA '90 = federal Medicaid floor: ProDUR + offer to counsel + profiles/retrospective DUR.

Seven screening families drive ProDUR questions.

Illinois practice layers > federal floor for ordinary community counseling—learn Illinois details in Chapter 9.

Resolve and document significant DUR hits; software does not replace the pharmacist.